Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York City. This ...

Investors in Pharming Group N.V. (AMS:PHARM) had a good week, as its shares rose 2.2% to close at €0.98 following the release of its third-quarter results. Revenues were US$53m, approximately in line ...

6 analysts have expressed a variety of opinions on Pharming (NASDAQ:PHAR) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick ...

Shares of Pharming Group N.V. Sponsored ADR (PHAR) have gained 24% over the past four weeks to close the last trading session at $17.06, but there could still be a solid upside left in the stock if ...

AMSTERDAM (Reuters) - Dutch biotechnology firm Pharming Group NV expects the European Medicines Agency to deny approval for its key drug Rhucin, it said on Thursday, sending its shares sharply down.

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pharming (NASDAQ:PHAR) in the last three months. The following table provides a quick overview ...

When we look around, we are amazed at the speed with which the world is changing. Online fraud techniques such as Pharming and other cybercrime attacks are at an all-time high. To overcome such ...

A rare immunodeficiency discovered just 10 years ago now has its first treatment. The FDA has approved a Pharming Group drug developed to treat activated phosphoinositide 3-kinase delta syndrome, or ...

The market offers strong growth potential driven by advancements in genetic engineering for efficient pharmaceutical protein ...

First came phishing scams, in which con artists hooked unwary internet users one by one into compromising their personal data. Now the latest cyberswindle, pharming, threatens to reel in entire ...